Sugi Predict

Sugi Predict / Compounds / SCHEMBL2340596

SCHEMBL2340596

SCHEMBL2340596

CCOC(=O)C(Br)Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP8 P22894 2/20 0.58
▸ L3MBTL1 Q9Y468 4/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ PIN1 Q13526 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.48
▸ EPHX2 P34913 1/20 0.48
▸ PPARG P37231 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ POLB P06746 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ PTPN7 P35236 1/20 0.47
▸ RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2555896 0.85 MMP8 (0.50) MMP8L3MBTL1SMN1; SMN2PIN1ALDH1A1
SCHEMBL6283432 0.84 MMP8 (0.59) MMP8L3MBTL1SMN1; SMN2PIN1ALDH1A1
SCHEMBL1008399 0.84 POLB (0.54) MMP8L3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL3316726 0.83 TSHR (0.52) MMP8L3MBTL1ALDH1A1PPARGTP53
Ethyl Acetate SCHEMBL6437598 0.83 ALDH1A1 (0.50) MMP8L3MBTL1SMN1; SMN2ALDH1A1EPHX2
SCHEMBL7104115 0.83 MMP8 (0.56) MMP8L3MBTL1SMN1; SMN2ALDH1A1EPHX2
SCHEMBL7104119 0.83 MMP8 (0.56) MMP8L3MBTL1SMN1; SMN2ALDH1A1EPHX2
SCHEMBL6439361 0.83 ALPI (0.54) MMP8L3MBTL1SMN1; SMN2ALDH1A1EPHX2
SCHEMBL305973 0.83 SMN1; SMN2 (0.55) MMP8L3MBTL1SMN1; SMN2PIN1ALDH1A1
SCHEMBL10523780 0.83 SMN1; SMN2 (0.55) MMP8L3MBTL1SMN1; SMN2PIN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119968368-A Amide compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2025-05-09 — — CN disclosed
US-12071413-B2 Azole derivatives as apelin receptor agonist Sanford Burnham Prebys Medical Discovery Institute (US) 2024-08-27 — — US disclosed
CN-117402156-A Amide compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-01-16 — — CN disclosed
WO-2024008196-A1 CLASS OF AMIDE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国科学院上海药物研究所 2024-01-11 — — WO disclosed
US-20230398233-A1 OCULAR ANTIBODY-DRUG CONJUGATES ADS THERAPEUTICS LLC (US) 2023-12-14 — — US disclosed
US-20230398233-A1 OCULAR ANTIBODY-DRUG CONJUGATES ADS THERAPEUTICS LLC (US) 2023-12-14 — — US disclosed
EP-3380970-B1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) 2023-01-04 — — EP disclosed
US-20220144784-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-05-12 — — US disclosed
US-11180479-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-11-23 — — US disclosed
US-11180479-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-11-23 — — US disclosed
EP-0266950-A2 Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1988-05-11 — — EP disclosed
CN-87101499-A Preparation method of n-statinib and n-cyclostatini polypeptide — 1988-05-11 — — CN disclosed
US-4705650-A DEACYLATION RHONE-POULENC SANTE (FR) 1987-11-10 — — US disclosed
US-4593098-A Piperazinone and piperazine polypeptides THE UPJOHN COMPANY (US) 1986-06-03 — — US disclosed
EP-0045165-B1 RHODANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITORS CONTAINING SUCH DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 1986-03-12 — — EP disclosed
US-4534897-A Piperazinone, piperazine, 1,4-diazepin-2-one and 1,4-diazepine intermediate compounds THE UPJOHN COMPANY (US) 1985-08-13 — — US disclosed
US-4446143-A Rhodanine derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1984-05-01 — — US disclosed
EP-0045165-A1 Rhodanine derivatives, a process for their preparation, and aldose reductase inhibitors containing such derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1982-02-03 — — EP disclosed
US-4251438-A ANALGESICS, PSYCHOTHERAPEUTIC AGENTS THE UPJOHN COMPANY (US) 1981-02-17 — — US disclosed
US-3946019-A ANTHELMINTIC, MICROBIOCIDES, ANTIBILHARZIAL RHONE-POULENC, S.A. (FR) 1976-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230398233-A1 OCULAR ANTIBODY-DRUG CONJUGATES UACA, CD40, TNFRSF9 MMP8 241/4885L3MBTL1 4811/4885SMN1; SMN2 4386/4885
US-11180479-B2 Antiviral compounds PLA2G1B, PLA2G4A, PLA2G4C MMP8 1802/4885L3MBTL1 1157/4885SMN1; SMN2 504/4885
US-12071413-B2 Azole derivatives as apelin receptor agonist APLNR, AGTR1, AGTR2 MMP8 2712/4885L3MBTL1 2222/4885SMN1; SMN2 4614/4885
US-20220144784-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST APLNR, AGTR1, AGTR2 MMP8 2677/4885L3MBTL1 2231/4885SMN1; SMN2 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.